PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K, CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED AND, WHERE APPLICABLE, HAVE BEEN BRACKETED. SUCH REDACTIONS ARE IMMATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Edison Oncology...License Agreement • November 22nd, 2022 • Apollomics Inc. • Pharmaceutical preparations • California
This License Agreement, dated January 31, 2021 (the “Effective Date”) is entered into by and between Edison Oncology Holding Corp., a Nevada corporation having an address at 3475 Edison Way, Suite R, Menlo Park CA 94025 (“Edison”) and Apollomics Inc., a Cayman corporation having an address at Cricket Square, Hutchins Drive, PO Box 2681, Grand Cayman KY1-111, Cayman Islands (“Apollomics”). Edison and Apollomics are also referred to individually as a “Party” and together as the “Parties”.
PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K, CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED AND, WHERE APPLICABLE, HAVE BEEN BRACKETED. SUCH REDACTIONS ARE IMMATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. TRI- PARTY AGREEMENTTri-Party Agreement • November 22nd, 2022 • Apollomics Inc. • Pharmaceutical preparations • Hong Kong
This Tri-Party Agreement (this “Agreement”) is made by and among Crown Bioscience (Taichang), Inc. (中美冠科生物技术（太仓）有限公司), a PRC limited liability company (“Licensor”), CB Therapeutics Inc., a Cayman company (“Licensee”), and Genor Biopharma Co., Ltd. (嘉和生物药业有限公司), a PRC limited liability company (“Genor”) (each of Licensor, Licensee, and Genor, a “Party” and collectively, the “Parties”).
SUBLEASESublease • November 22nd, 2022 • Apollomics Inc. • Pharmaceutical preparations • California
COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN APOLLOMICS, INC. AND REVMAB BIOSCIENCES USA, INC. November 12, 2019Collaboration and License Agreement • November 22nd, 2022 • Apollomics Inc. • Pharmaceutical preparations • California
This Collaboration and License Agreement (the “Agreement”) is made and entered into as of the 12th day of November 2019 (the “Effective Date”) between Apollomics Inc. a Cayman corporation having its principal place of business at Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands including its subsidiaries (“Apollomics”), and the RevMAb Biosciences USA, Inc., a California corporation, having a place of business at 830 Dubuque Ave, South Sand Francisco, CA 940280 (“RevMab”). Apollomics and RevMab are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDED & RESTATED LICENCE AND CO-DEVELOPMENT AGREEMENTLicence and Co-Development Agreement • November 22nd, 2022 • Apollomics Inc. • Pharmaceutical preparations • England
This Amended and Restated Licence and Co-Development Agreement (the “Agreement”) is entered into by and between TYG oncology Ltd., a UK Limited Company (“TYG” or “Licensor”), with its address at Synergy House 7 Acorn Business Park Commercial Gate Mansfield, Nottinghamshire NG 18 1EX UK; and Apollomics (Hong Kong) Limited, a Hong Kong entity (with company number 2844212) having one of its places of business at 989 E Hillsdale Blvd, Ste 220, Foster City, CA 94404, USA (“Apollomics”), as of the date last signed by the parties hereto (the “Amendment Date”) and amends and restates the Original Agreement (as defined below).
TECHNOLOGY TRANSFER AND CO-DEVELOPMENT AGREEMENT BY AND BETWEEN APOLLOMICS (HONG KONG), LIMITED AND NUANCE BIOTECH INC. AND NUANCE BIOTECH (SHENZHEN) CO., LTD. AND NUANCE BIOTECH (NANTONG) CO., LTD. DATED AS OF JANUARY 25 2021Technology Transfer and Co-Development Agreement • November 22nd, 2022 • Apollomics Inc. • Pharmaceutical preparations • New York
This Technology Transfer and Co-Development Agreement (this “Agreement”) is entered into as of January 25, 2021 (the “Closing Date”) by and among (a), APOLLOMICS (HONG KONG), LIMITED, a Hong Kong entity along with its Affiliates having one of its places of business at 989 East Hillsdale Blvd. Suite 220, Foster City, CA 94404 (“Apollomics”), and (b) Nuance Biotech Inc. (“Nuance Cayman”), a Cayman Islands company; (c) Nuance Biotech (Shenzhen) Co., Ltd., a PRC company with its registered office at Unit 1505, Block A, Innovation Plaza, No. 2007 Pingshan Avenue, Pingshan District, Shenzhen, PRC (“Nuance Shenzhen”); and (d) Nuance Biotech (Nantong) Co. Ltd, a PRC company with its registered office at Building A1, 100 Dongting Lake Road, Linjiang Town, Haimen Distric, Nantong City, Jiangsu Province, China (“Nuance Nantong”, and collectively, with Nuance Cayman and Nuance Shenzhen, “Nuance”). Apollomics and Nuance are referred to herein individually as a “Party” and collectively as the “Parti
PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K, CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED AND, WHERE APPLICABLE, HAVE BEEN BRACKETED. SUCH REDACTIONS ARE IMMATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. DATA SUBLICENSE...Data Sublicense Agreement • November 22nd, 2022 • Apollomics Inc. • Pharmaceutical preparations • California
This Data Sublicense Agreement (this “Agreement”) is made by and between Crown Bioscience (Taichang), Inc. (中美冠科生物技术（太仓）有限公司), a PRC limited liability company (“Licensor”), and CB Therapeutics Inc., a Cayman company (“Licensee”) (each of Licensor and Licensee, a “Party” and collectively, the “Parties”).
